Jaguar Health, Inc. announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International. A European pharmaceutical industry leader and entrepreneur with more than 35 years experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, Dr. Radaelli is a member of the board of directors of Napo Therapeutics, the Jaguar family company established in Italy in 2021 that focuses on expanding crofelemer access in Europe, and temporarily served as Napo Therapeutics Interim Executive Director. Dr. Radaelli s core focus will be to further expand Jaguar s commercial footprint outside the U.S. and increase access to prescription pharmaceuticals for essential supportive care and management of neglected symptoms across multiple complicated disease states - such as cancer, short bowel syndrome (SBS), and microvillus inclusion disease (MVID) - to people in need around the world.

In April 2023 Dr. Radaelli was named Commander of the Italian Republic for Special Merits, the highest-ranking honor of the Italian Republic bestowed upon a civilian by the President of the Republic of Italy and the Prime Minister of Italy, in recognition for merit acquired in the fields of Science and the BioPharma Industry with a particular focus in Rare and Neglected diseases. Dr. Radaelli founded Noventia Pharma in 2009 and serves as its Chairman, President, and Chief Executive Officer. He also founded Pint Pharma Group and Ferrer Italia and was co-founder of a Dupont-Merck JV Italian subsidiary.

He served as the President and Chief Executive Officer of Dompe International SA., the International Pharmaceutical Company of the Dompe Group. He joined Dompe in 1996 as Director of Corporate Business Development and was responsible for the initiation of Dompe s global strategy in its Swiss subsidiary and for its strategic planning, licensing, alliances, and new-product opportunities in Europe. Dr. Radaelli held various Executive positions, including Sales Marketing, at the Dupont-Merck Pharmaceutical Company, Hoffman-La Roche Ltd., and the Menarini Group.

He serves as the Executive Chairman of Bioakos Pharma. He has served as a Director of Dompe Farmaceutici SpA, Dompe SpA and Philogen SpA, a privately held Italian biopharmaceutical company. Dr. Radaelli served as a Director and Deputy Chair of IDRI, a non-profit organization focused on neglected diseases.

He served as an Independent Director of Ariad Pharmaceuticals from October 2008 until July 2016, and as a Director of NovaBay Pharmaceuticals from January 2014 until May 2016. Dr Radaelli was a founder and he served on the Board of Directors of Pint Pharma and Cytovia Therapeutics. Before joining Jaguar Health Dr. Radaelli was SVP President International of Immunogen, which is now part of Abbvie.

Dr. Radaelli received a University Degree in Pharmaceutical Sciences and a Ph.D. in Clinical Pharmacology from the University of Milan and an Executive Master of Business from Bocconi University of Milan.